Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How much fat loss is needed for lipoatrophy to become clinically evident?
Podzamczer D, Ferrer E, Martínez E, Del Rio L, Rosales J, Curto J, Ribera E, Barrufet P, Llibre JM, Aranda M; ABCDE Study Team. Podzamczer D, et al. Among authors: del rio l. AIDS Res Hum Retroviruses. 2009 Jun;25(6):563-7. doi: 10.1089/aid.2008.0264. AIDS Res Hum Retroviruses. 2009. PMID: 19500014 Free article.
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L; ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team. Podzamczer D, et al. Among authors: del rio l. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):139-47. doi: 10.1097/QAI.0b013e31802bf122. J Acquir Immune Defic Syndr. 2007. PMID: 17106274 Clinical Trial.
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Ferrer E, del Rio L, Martínez E, Curto J, Domingo P, Ribera E, Negredo E, Rosales J, Saumoy M, Ordóñez J, Gatell JM, Podzamczer D. Ferrer E, et al. Among authors: del rio l. AIDS Res Hum Retroviruses. 2011 Oct;27(10):1061-5. doi: 10.1089/AID.2010.0254. Epub 2011 Jan 15. AIDS Res Hum Retroviruses. 2011. PMID: 21166602 Free article.
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Miralles C, Domingo P, Montero M, del Rio L, Fontdevila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E. Rojas J, et al. Among authors: del rio l. HIV Med. 2016 May;17(5):340-9. doi: 10.1111/hiv.12314. Epub 2015 Sep 10. HIV Med. 2016. PMID: 27089862 Free article. Clinical Trial.
Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.
Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo GM, Villarroya J, de los Santos I, Domingo JC, Villarroya F, Del Rio L, Estrada V, Giralt M. Domingo P, et al. Among authors: del rio l. PLoS One. 2014 Feb 26;9(2):e89088. doi: 10.1371/journal.pone.0089088. eCollection 2014. PLoS One. 2014. PMID: 24586518 Free PMC article.
316 results